Why diagnosis codes alone fall short for long COVID surveillance
When our client, a global pharmaceutical company, set out to better understand long COVID pathways,...
When our client, a global pharmaceutical company, set out to better understand long COVID pathways,...
by: Alexandra Miller, MPH Human papillomavirus (HPV) is one of the most common sexually...
When two federal agencies, the National Center for Science and Engineering Statistics (NCSES) and...
Why real-world data matters in epilepsy research Epilepsy affects millions of adults in the United...
Understanding disparities in opioid use disorder (OUD) treatment Pharmaceutical companies committed...
Antiretroviral therapy (ART) has transformed outcomes for people living with HIV, especially those...
Mapping food allergy care with omalizumab and real-world data IgE-mediated food allergies (FAs)...
High-risk NMIBC: Disease overview and treatment approach Johnson & Johnson quickly identified and...
Government health agencies are increasingly turning to real-world data (RWD) for public health...
A new peer-reviewed study from the Centers for Disease Control and Prevention (CDC) highlights the...
A better way to measure healthcare costs in closed claims data This is the second post in our four-part taXonomy X blog series (part 1 here), and here we’ll discuss one of the most common pain points in closed claims analytics: costs. Specifically, w...